Therefore, tumors with BRAF or KRAS mutations were in correlation with elevated serum level of tumor biomarkers of CRC and the association of tumor biomarkers and molecular status may indicate the poor prognosis of these patients. The gene discussed is KRAS; the disease is colorectal carcinoma.